Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
Hormonal Regulation of Blood Pressure01:17

Hormonal Regulation of Blood Pressure

Endocrinal or hormonal intervention in the cardiovascular system is predominantly exerted by the catecholamines - epinephrine and norepinephrine, as well as a slew of hormones that interact with renal function to modulate blood volume.
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction while...
Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
Hypertension I: Introduction01:28

Hypertension I: Introduction

Hypertension is a widespread, long-term medical condition where blood pressure in the arteries remains elevated. It is characterized by systolic blood pressure readings of 130 mm Hg or above or diastolic blood pressure (DBP) readings of 80 mm Hg or higher. Unmanaged hypertension poses significant health risks, making the distinction between primary (or essential) hypertension and secondary hypertension crucial, as their management and implications vary.Primary HypertensionPrimary hypertension,...
Hormonal Regulation01:33

Hormonal Regulation

The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Consensus and controversies about diagnosing GH deficiency: a Delphi survey by the GH research society.

Pituitary·2025
Same author

Medical management pathways for Cushing's disease in pituitary tumors centers of excellence (PTCOEs).

Pituitary·2025
Same author

Standards of care for medical management of acromegaly in pituitary tumor centers of excellence (PTCOE).

Pituitary·2024
Same author

Pilot study to define criteria for Pituitary Tumors Centers of Excellence (PTCOE): results of an audit of leading international centers.

Pituitary·2023
Same author

Non-overweight depressed patients who respond to antidepressant treatment have a higher risk of later metabolic syndrome: findings from the METADAP cohort.

Psychological medicine·2023
Same author

ESE Clinical Practice Guideline on functioning and nonfunctioning pituitary adenomas in pregnancy.

European journal of endocrinology·2021
Same journal

[18F]F-DOPA and [18F]F-FDG PET/CT for staging advanced medullary thyroid cancer.

Annales d'endocrinologie·2026
Same journal

Corrigendum to 'Pink adipose tissue: A paradigm of adipose tissue plasticity' [Ann. Endocrinol. 85 (2004) 248-51].

Annales d'endocrinologie·2026
Same journal

Intraoperative location of parathyroid glands during total thyroidectomy: a systematic review of the literature according to the PRISMA method.

Annales d'endocrinologie·2026
Same journal

Clinical and genetic diagnosis of PHP1A associated with hypogonadism in a young male: A case report.

Annales d'endocrinologie·2026
Same journal

Autoimmune features in acquired generalized lipodystrophy and anti-perilipin 1 antibodies: A case report.

Annales d'endocrinologie·2026
Same journal

The diagnostic challenge of occult glucocorticoid exposure causing Cushing's syndrome.

Annales d'endocrinologie·2026
See all related articles

Related Experiment Video

Updated: May 17, 2026

The Antihypertensive Effects and Mechanisms of Huotan Jiedu Tongluo Decoction in Rats with H-Type Hypertension
05:57

The Antihypertensive Effects and Mechanisms of Huotan Jiedu Tongluo Decoction in Rats with H-Type Hypertension

Published on: May 17, 2024

[Update on endocrine hypertension].

A Al-Salameh1, R Cohen, P Chanson

  • 1Service d'Endocrinologie, Diabétologie et Maladies Métaboliques, Hôpital Avicenne, AP-HP, 125 route de Stalingrad, 93009 Bobigny, France. abdallahalsalameh@hotmail.com

Annales D'Endocrinologie
|October 24, 2012
PubMed
Summary
This summary is machine-generated.

Endocrine hypertension, including primary hyperaldosteronism and pheochromocytoma, increases cardiovascular risk. Recent genetic research advances diagnosis and management for these conditions.

Related Experiment Videos

Last Updated: May 17, 2026

The Antihypertensive Effects and Mechanisms of Huotan Jiedu Tongluo Decoction in Rats with H-Type Hypertension
05:57

The Antihypertensive Effects and Mechanisms of Huotan Jiedu Tongluo Decoction in Rats with H-Type Hypertension

Published on: May 17, 2024

Area of Science:

  • Endocrinology
  • Genetics
  • Cardiovascular Medicine

Background:

  • Endocrine hypertension is the most common cause of secondary hypertension (~3% of population).
  • Primary hyperaldosteronism and pheochromocytoma are key endocrine causes, both associated with increased cardiovascular risk compared to essential hypertension.
  • Timely diagnosis and specific treatments are crucial for managing these conditions.

Purpose of the Study:

  • To review recent advancements in understanding and managing primary hyperaldosteronism and pheochromocytoma.
  • To highlight the impact of genetic discoveries on the pathophysiology and clinical care of these endocrine disorders.
  • To emphasize the importance of accurate diagnosis due to shared cardiovascular risks.

Main Methods:

  • Review of recent research on KCNJ5 gene mutations in primary hyperaldosteronism.
  • Analysis of genetic abnormalities and phenotypic clustering in pheochromocytoma.
  • Discussion of diagnostic challenges and therapeutic implications.

Main Results:

  • Somatic mutations in KCNJ5 are confirmed to play a role in aldosterone hypersecretion, though their role in adenoma formation requires further study.
  • Genetic abnormalities are identified in up to 50% of pheochromocytoma patients, revealing distinct genotypic and phenotypic clusters.
  • Progress in understanding pathogenesis aids in patient management and follow-up.

Conclusions:

  • Recent genetic insights are improving the understanding and diagnosis of primary hyperaldosteronism and pheochromocytoma.
  • Continued research into the pathogenesis of these endocrine hypertensive diseases is essential for optimizing patient care.
  • Advances in genetics significantly impact the clinical management and prognosis of patients with endocrine hypertension.